Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer
Open Access
- 15 June 2017
- journal article
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 31 (12), 1228-1242
- https://doi.org/10.1101/gad.299958.117
Abstract
Androgen receptor (AR) signaling reprograms cellular metabolism to support prostate cancer (PCa) growth and survival. Another key regulator of cellular metabolism is mTOR, a kinase found in diverse protein complexes and cellular localizations, including the nucleus. However, whether nuclear mTOR plays a role in PCa progression and participates in direct transcriptional cross-talk with the AR is unknown. Here, via the intersection of gene expression, genomic, and metabolic studies, we reveal the existence of a nuclear mTOR-AR transcriptional axis integral to the metabolic rewiring of PCa cells. Androgens reprogram mTOR-chromatin associations in an AR-dependent manner in which activation of mTOR-dependent metabolic gene networks is essential for androgen-induced aerobic glycolysis and mitochondrial respiration. In models of castration-resistant PCa cells, mTOR was capable of transcriptionally regulating metabolic gene programs in the absence of androgens, highlighting a potential novel castration resistance mechanism to sustain cell metabolism even without a functional AR. Remarkably, we demonstrate that increased mTOR nuclear localization is indicative of poor prognosis in patients, with the highest levels detected in castration-resistant PCa tumors and metastases. Identification of a functional mTOR targeted multigene signature robustly discriminates between normal prostate tissues, primary tumors, and hormone refractory metastatic samples but is also predictive of cancer recurrence. This study thus underscores a paradigm shift from AR to nuclear mTOR as being the master transcriptional regulator of metabolism in PCa.Keywords
Funding Information
- Terry Fox Research Institute (116128)
- Canadian Institutes of Health Research (MOP-111144)
- Consortium Québecois pour la Découverte de Médicaments
- New Innovation Fund (CFI 21875)
- McGill Urology Research
- CIHR
- McGill Integrated Cancer Research
This publication has 67 references indexed in Scilit:
- Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune ResponseEuropean Urology, 2017
- AR-Signaling in Human Malignancies: Prostate Cancer and BeyondCancers, 2017
- Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancerOncotarget, 2016
- The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic CarcinomaThe American Journal of Surgical Pathology, 2016
- The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesisNature Genetics, 2015
- The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesisThe EMBO Journal, 2011
- A Pituitary-Specific Enhancer of the POMC Gene with Preferential Activity in Corticotrope CellsMolecular Endocrinology, 2011
- Nutrient regulates Tor1 nuclear localization and association with rDNA promoterNature, 2006
- Gene expression profiling identifies clinically relevant subtypes of prostate cancerProceedings of the National Academy of Sciences of the United States of America, 2004
- The LNCaP cell line--a new model for studies on human prostatic carcinoma.1980